BioCentury This Week

BioCentury Podcasts
  • 5.0 (25)
  • 生命科学
  • 一周一更
BioCentury This Week

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

  1. Ep. 265 - RFK Jr. & HHS, Blenrep's Comeback, China Deals

    5天前

    Ep. 265 - RFK Jr. & HHS, Blenrep's Comeback, China Deals

    Giving RFK Jr. control of HHS would be disastrous, argues Washington Editor Steve Usdin on the latest BioCentury This Week podcast. Expanding on his Editor’s Commentary, Usdin explains why Kennedy would be an unmitigated disaster for FDA, NIH and CMS, for biopharmas and for patients. He calls on biopharma leaders to speak out and affirm basic truths, even if it puts them in harm’s way.BioCentury’s editors also discuss why new data for GSK's Blenrep — an oncology therapy withdrawn two years ag...

    30 分钟
  2. Ep. 264 - Prepping for Trump & Alzheimer's Ethics

    11月12日

    Ep. 264 - Prepping for Trump & Alzheimer's Ethics

    Trump 2.0 presents opportunities and challenges for leaders of the biopharma industry, which needs effective public policy to thrive. On the latest BioCentury This Week, BioCentury Washington Editor Steve Usdin explains what those opportunities are and lays out the potential impact on the public policy environment, which could have repercussions on FDA and beyond.BioCentury’s editors then analyze how companies, academics and advocates are pushing back on claims that they should have disclosed...

    29 分钟
  3. Ep. 263 - Alzheimer Insights: Anti-Amyloid Safety & Tau Teaser

    11月5日

    Ep. 263 - Alzheimer Insights: Anti-Amyloid Safety & Tau Teaser

    It’s too soon to conclude anti-amyloid therapies are safe for use by Alzheimer’s patients in the real world, even as early reports are encouraging, argues BioCentury Executive Editor Selina Koch on the latest BioCentury This Week podcast. Koch and colleagues discuss takeaways from this year’s Clinical Trials on Alzheimer’s Disease annual meeting, including conclusions from adverse event data for Leqembi lecanemab and what the true test of appropriate use and safety for the drug might look lik...

    35 分钟
  4. Ep. 262 - EGFR Case Study, FDA & Politics

    10月29日

    Ep. 262 - EGFR Case Study, FDA & Politics

    Twenty years of innovation in therapies targeting EGFR provides a case study in how generation of differentiated products against the target can drive market growth. On the latest BioCentury This Week podcast, BioCentury’s editors discuss EGFR as a prime example of the value in best-in-class development strategies, with meaningful improvements across multiple modalities delivering substantial therapeutic benefits to patients. Analogous best-in-class opportunities aren’t limited to cancer, but...

    24 分钟
  5. Ep. 261 - China Summit: Reinventing Your China Strategy

    10月24日

    Ep. 261 - China Summit: Reinventing Your China Strategy

    Cross-border geopolitical tensions and a prolonged capital crunch are compelling biopharma companies from Beijing to Boston to rethink their strategies on everything from deal-making and raising capital to manufacturing and use of CROs. On a special edition of the BioCentury This Week podcast, McKinsey’s Franck Le Deu and Wendy Pan of BayHelix and Goodwin join BioCentury on the eve of next week’s eleventh annual BioCentury-BayHelix China Healthcare Summit in Shanghai to discuss the dynamics a...

    32 分钟
  6. Ep. 260 - VC Funds, New Chapter for MS, Wave's Data

    10月22日

    Ep. 260 - VC Funds, New Chapter for MS, Wave's Data

    At least 25 venture firms have raised a total of more than $17 billion in funds this year, with Forbion unveiling the largest-ever European biopharma fund at €1.2 billion last week. On the latest BioCentury This Week podcast, BioCentury’s editors discuss how Forbion deployed its prior fund and quickly raised fresh funds and what that — and other funds — say about the state of financing private biotechs in Europe and elsewhere.The editors then assess takeaways from BioCentury’s conversation wi...

    31 分钟
  7. Ep. 259 - Causal Biology and Big Data, Ultra-Rare Drugs at FDA

    10月15日

    Ep. 259 - Causal Biology and Big Data, Ultra-Rare Drugs at FDA

    There is a growing mandate among researchers and VCs to provide proof of causal human biology for new targets. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the different strategies being deployed to identify causal links to disease using observational patient data or human cell models, including the challenges that come with each approach and the various computational methodologies companies are using.They also discuss the outcome of FDA’s advisory committee meetin...

    34 分钟
  8. Ep. 258 - Breaking the Bear: 4Q Public Markets Preview

    10月8日

    Ep. 258 - Breaking the Bear: 4Q Public Markets Preview

    Biopharma buysiders and bankers at long last believe the conditions are ripe for biotech growth and outperformance, BioCentury’s Stephen Hansen says on the latest BioCentury This Week podcast. Hansen and colleagues take stock of the sector’s growth potential after three long years of the bear market as they discuss BioCentury’s 4Q24 Public Markets Preview.Also on this week’s show, Washington Editor Steve Usdin discusses his Editor’s Commentary, in which he argues that FDA leaders planned refo...

    40 分钟
查看全部 274 集

5
共 5 分
25 个评分

关于

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

信息

更多来自“BioCentury Podcasts”的内容

你可能还喜欢

若要收听包含儿童不宜内容的单集，请登录。

关注此节目的最新内容

登录或注册，以关注节目、存储单集，并获取最新更新。
选择国家或地区

非洲、中东和印度

亚太地区

欧洲

拉丁美洲和加勒比海地区

美国和加拿大